Immunophotonics is a private biotechnology company that is developing a proprietary carbohydrate polymer (IP-001) for use after a common tumor ablation procedure to induce a systemic anti-tumor immune response. Immunophotonics has subsidiaries in Bern, Switzerland and Tianjin, China. We are a multidisciplinary team of highly experienced individuals committed to pioneering the future of cancer immunotherapy.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.